1 active not recruiting, 1 recruiting. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Active not recruiting 1 |
Follow Uterine Adenocarcinoma: new trials by email Literature Review of Uterine Adenocarcinoma trials Research Report on Uterine Adenocarcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Clonal Hematopoiesis Chemotherapy and Radiation Effects Study Samples - Lung Cancer (Diagnosis), Osteochondroma | Recruiting | Dana-Farber Cancer Institute | 5000 | 2025-04-04 | 2026-06-30 | |
| Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors Spartalizumab, Tislelizumab - MSI-H Colorectal Cancer, Melanoma | Phase 2 | Active not recruiting | SOLTI Breast Cancer Research Group | 184 | 2021-04-12 | 2025-03-21 |
Adenocarcinoma Of Esophagus (2) · Sarcoma (2) · Adenocarcinoma of Lung (1) · Anus Neoplasms (1) · Breast Neoplasms (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Ovarian Epithelial (1) · Carcinoma, Renal Cell (1) · Carcinoma, Transitional Cell (1) · Cholangiocarcinoma (1) · Colonic Neoplasms (1) · Disease (1) · Head and Neck Neoplasms (1) · Lung Neoplasms (1) · Melanoma (1)
Breast Diseases (2) · Colorectal Neoplasms (2) · Digestive System Diseases (2) · Digestive System Neoplasms (2) · Gastrointestinal Diseases (2) · Gastrointestinal Neoplasms (2) · Intestinal Diseases (2) · Intestinal Neoplasms (2) · Lung Diseases (2) · Neoplasms (2) · Neoplasms by Histologic Type (2) · Neoplasms by Site (2) · Neoplasms, Connective and Soft Tissue (2) · Nevi and Melanomas (2) · Pathologic Processes (2)
Sampling Studies (1) · spartalizumab (1) · tislelizumab (1)
Dana-Farber Cancer Institute (1) · SOLTI Breast Cancer Research Group (1)
Spain (1) · United States (1)